Market news

Activists recently filed disclosures with the SEC that included Privia Health Group (PRVA), putting fresh attention on the physician-enablement specialist and how its shares trade around the latest ownership updates. At around US$19.85 per share, Privia Health Group has been under pressure, with the share price falling 6.4% over the past month and 16.1% over the last quarter. The 1-year total shareholder return is down 11.3%, pointing to fading momentum that may reflect investors reassessing...

Privia Health Group shares most recently closed at US$19.85, and the weaker run in the stock raises a straightforward question for investors who care about valuation. Is the current price fully supported by the earnings profile of Privia Health Group, or has sentiment moved further than the underlying profit story? Over the past 5 years the share price has fallen 23.1%, which puts the focus firmly on whether the current earnings justify staying invested or stepping in now. The business model...

Detailed price information for Capital One Financial (COF-N) from The Globe and Mail including charting and trades.

Looking back on healthcare technology for providers stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Privia Health (NASDAQ:PRVA) and its peers.

Privia Health has been treading water for the past six months, recording a small loss of 1.7% while holding steady at $21.63. The stock also fell short of the S&P 500’s 11.3% gain during that period.

Detailed price information for Privia Health Group Inc (PRVA-Q) from The Globe and Mail including charting and trades.

Dr. Ernest Brings Significant Value-based Care and Clinical ExpertiseARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026. She has also been named a member of the Compliance Committee of the Board.“We are excited to welcome Dr. Ernest to our Board of Directors,” said David King, Chairman of the Board, Privia Health Group, Inc. “She brings valuable clinical

Privia Health’s second quarter results were met with a negative market reaction as investors digested the company’s strong revenue growth alongside a material shortfall in non-GAAP profit relative to Wall Street expectations. Management attributed the top-line performance to robust provider signings and expanded value-based attributed lives, noting that implemented provider growth of 10.1% and value-based attributed lives growth of 19.2% drove overall practice collections. CEO Parth Mehrotra poi

Privia Health (NASDAQ:PRVA) just turned in a quarter that checked every box management set for itself, and then raised the bar again for the rest of the year. On the company’s August 6 earnings call, CEO Parth Mehrotra and CFO David Mountcastle laid out a business adding doctors, patients, and cash at a pace that […]

Motley Fool Press Release.

Detailed price information for Privia Health Group Inc (PRVA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Privia Health Group Inc (PRVA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Privia Health Group Inc (PRVA-Q) from The Globe and Mail including charting and trades.

Privia Health (PRVA) shares fell 13% in Thursday trading after the company reported Q2 adjusted earn

Privia Health (PRVA) delivered earnings and revenue surprises of -12.50% and +8.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare tech company Privia Health Group (NASDAQ:PRVA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 21.4% year on year to $632.6 million. Its non-GAAP profit was $0.19 per share.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

2Q’26 Net Income of $9.0M, +236.7% from 2Q’252Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25Full-Year 2026 Guidance Raised for All Key Financial Metrics ARLINGTON, Va., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the second quarter and six-month periods ended June 30, 2026. Second Quarter Performance Three Months Ended June 30, (unaudited; $ in millions, except per share amounts) 2026 2025 Change (%)*Total revenue $632.6 $52

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Privia Health Group Inc (PRVA-Q) from The Globe and Mail including charting and trades.

Warning: RSI is above 70 for 3 overbought stocks in healthcare. Progyny, 10X Genomics, and Privia Health have high RSI values and strong price action.

Detailed price information for Privia Health Group Inc (PRVA-Q) from The Globe and Mail including charting and trades.

This healthcare services provider, focused on value-based care, reported a notable insider sale amid a year of double-digit stock gains.

Detailed price information for Privia Health Group Inc (PRVA-Q) from The Globe and Mail including charting and trades.

ARLINGTON, Va., July 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its second-quarter and six-month periods ended June 30, 2026 before market open on Thursday, August 6, 2026. The press release is expected to be publicly disseminated by 7:00 am ET and will also be available on the Company’s Investor Relations website at ir.priviahealth.com. Privia Health management will host a conference call beginning at 8: